Post by Bayer | Pharmaceuticals

#TeamBayer, together with Vividion Therapeutics, Inc. is excited to advance next stage of clinical development of an investigational WRN helicase inhibitor targeting colorectal cancer (CRC) with high microsatellite instability (MSI-high). CRC is the third most common cancer worldwide, with nearly two million new cases diagnosed each year. This innovative approach aims to deliver lethal DNA damage to cancer cells while minimizing harm to healthy cells, offering a more targeted treatment option for patients with cancers such as colorectal, endometrial, ovarian and gastric tumors. Advancing precision oncology therapies for cancers driven by specific molecular vulnerabilities is a key focus of Bayer’s oncology strategy.

Video Content